ReviewClinical cancer research : an official journal of the American Association for Cancer Research2016
Gene Expression Profiles in Myeloma: Ready for the Real World?
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data.Scientific reports · 2021Pooled it
- Novel proteomic characterization of multiple myeloma bone marrow interstitial fluid links prognosis to coagulation pathways.Clinical proteomics · 2025Article
- Prognostic impact of a senescence gene signature in multiple myeloma.GeroScience · 2025Article
- Enhancing staging in multiple myeloma using an m6A regulatory gene-pairing model.Clinical and experimental medicine · 2025Article
- Identifying high-risk multiple myeloma patients: A novel approach using a clonal gene signature.International journal of cancer · 2024Article
- Enhancing multiple myeloma staging: a novel cell death risk model approach.Clinical and experimental medicine · 2024Article
- Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing.Blood cancer journal · 2024Article
- Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Mouse models of human multiple myeloma subgroups.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).Pathology oncology research : POR · 2023Article
- RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.Frontiers in immunology · 2023Article
- Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients.International journal of molecular sciences · 2022Article
- Identification of a drug-response gene in multiple myeloma through longitudinal single-cell transcriptome sequencing.iScience · 2022Article
- Gene expression profiling and in vitro functional studies reveal RAD54L as a potential therapeutic target in multiple myeloma.Genes & genomics · 2022Article
- Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk.Annals of hematology · 2022Review
- Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence.Leukemia · 2022Article
- High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.Blood cancer journal · 2022Review
- Using MMRFBiolinks R-Package for Discovering Prognostic Markers in Multiple Myeloma.Methods in molecular biology (Clifton, N.J.) · 2022Article
- The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications.International journal of molecular sciences · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Multiple myeloma is a plasma cell malignancy characterized by molecular and clinical heterogeneity. The outcome of the disease has been dramatically improved with the advent of new drugs in the past few years. However, even in this context of increasing therapeutic options, important challenges remain, such as accurately evaluating patients' prognosis and predicting sensitivity to specific treatments and drug combinations. Transcriptomic studies have largely contributed to help decipher multiple myeloma complexity, characterizing multiple myeloma subgroups distinguished by different outcomes. Microarrays and, more recently, RNA sequencing allow evaluation of expression of coding and noncoding genes, alternate splicing events, mutations, and novel transcriptome modifiers, providing new information regarding myeloma biology, prognostication, and therapy. In this review, we discuss the role and impact of gene expression profiling studies in myeloma. Clin Cancer Res; 22(22); 5434-42. ©2016 AACR SEE ALL ARTICLES IN THIS CCR FOCUS SECTION, "MULTIPLE MYELOMA MULTIPLYING THERAPIES".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.